Quick Answer
ANI PHARMACEUTICALS INC reported Operating Income Loss of $111.09 million for the year ending 2025.
- ANI PHARMACEUTICALS INC showed an increase of +18,922.8% in Operating Income Loss from 2024 to 2025.
- This data is from ANI PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), ANI PHARMACEUTICALS INC's Operating Income Loss has grown by 264,607.1%.
- Historical annual values: Fiscal year 2025: $111.09 million | Fiscal year 2024: $584.0 thousand | Fiscal year 2023: $46.97 million | Fiscal year 2022: -$35.28 million | Fiscal year 2021: -$39.79 million | Fiscal year 2020: -$16.02 million | Fiscal year 2019: $16.35 million | Fiscal year 2018: $35.36 million | Fiscal year 2017: $28.33 million | Fiscal year 2016: $20.08 million | Fiscal year 2015: $32.70 million | Fiscal year 2014: $20.01 million | Fiscal year 2013: $898.0 thousand | Fiscal year 2012: -$42.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: